[144] Quest Diagnostics Inc. SEC Filing
Quest Diagnostics (DGX) Form 144 notice shows a proposed sale of 72 shares of common stock through Fidelity Brokerage (approximate aggregate market value $12,960.00) with an approximate date of sale of 08/15/2025. The filer reports prior acquisitions via the company's ESPP: 12 shares acquired 01/31/2022 and 60 shares acquired 07/19/2024, both paid in cash. The filing also discloses a recent sale by Thomas P. Plewman of 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references trading-plan/Rule 10b5-1 provisions but does not state a plan adoption date.
Quest Diagnostics (DGX) 鈥� Un avviso Form 144 indica la proposta di vendita di 72 azioni ordinarie tramite Fidelity Brokerage (valore di mercato aggregato stimato $12.960,00) con data approssimativa di vendita il 15/08/2025. Il dichiarante segnala acquisti precedenti tramite l'ESPP dell'azienda: 12 azioni acquistate il 31/01/2022 e 60 azioni acquistate il 19/07/2024, entrambe pagate in contanti. La comunicazione riporta anche una recente vendita da parte di Thomas P. Plewman di 5.535 azioni in data 06/08/2025 per proventi lordi pari a $968.625,00. L'avviso include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali negative non divulgate e menziona disposizioni relative a un piano di trading/Rule 10b5-1, senza per貌 indicarne la data di adozione.
Quest Diagnostics (DGX) 鈥� Un aviso Form 144 muestra una propuesta de venta de 72 acciones ordinarias a trav茅s de Fidelity Brokerage (valor de mercado agregado aproximado $12,960.00) con fecha aproximada de venta el 15/08/2025. El declarante informa adquisiciones previas mediante el ESPP de la compa帽铆a: 12 acciones adquiridas el 31/01/2022 y 60 acciones adquiridas el 19/07/2024, ambas pagadas en efectivo. La presentaci贸n tambi茅n divulga una venta reciente por parte de Thomas P. Plewman de 5,535 acciones el 06/08/2025 por ingresos brutos de $968,625.00. El aviso incluye la declaraci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada y hace referencia a disposiciones de un plan de negociaci贸n/Rule 10b5-1, sin especificar la fecha de adopci贸n del plan.
Quest Diagnostics (DGX) 鈥� Form 144 瓿奠嫓电� Fidelity Brokerage毳� 韱淀暣 氤错喌欤� 72欤�毳� 毵る弰頃� 鞓堨爼鞛勳潉 氤挫棳欤茧┌(雽�霝� 頃╈偘 鞁滉皜 齑濎暋 $12,960.00) 毵る弰 鞓堨爼鞚检潃 2025-08-15搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛惖鐢 須岇偓 ESPP毳� 韱淀暣 鞚挫爠鞐� 旆摑頃� 雮挫棴鞚� 氤搓碃頄埖鐢雿�, 12欤�电� 2022-01-31鞐�, 60欤�电� 2024-07-19鞐� 順勱笀鞙茧 旆摑頄堨姷雼堧嫟. 鞝滌稖靹滌棎电� 霕愴暅 Thomas P. Plewman鞚� 2025-08-06鞐� 5,535欤�毳� 毵る弰頃� 齑濎垬鞚� $968,625.00毳� 鞓Π 靷嫟鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓿奠嫓电� 毵る弰鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 響滌鞝侅溂搿� 歆勳垹頃橁碃 鞛堨溂氅�, 瓯半灅瓿勴殟/Rule 10b5-1 臁绊暛鞚� 鞏戈笁頃橂倶 瓿勴殟 毂勴儩鞚检潃 氇呾嫓頃橃 鞎婌晿鞀惦媹雼�.
Quest Diagnostics (DGX) 鈥� Un avis Form 144 indique un projet de vente de 72 actions ordinaires via Fidelity Brokerage (valeur de march茅 agr茅g茅e approximative $12,960.00) avec une date de vente approximative au 15/08/2025. Le d茅clarant signale des acquisitions ant茅rieures via le plan ESPP de la soci茅t茅聽: 12 actions acquises le 31/01/2022 et 60 actions acquises le 19/07/2024, toutes deux pay茅es en esp猫ces. Le d茅p么t r茅v猫le 茅galement une vente r茅cente par Thomas P. Plewman de 5 535 actions le 06/08/2025 pour des produits bruts de $968,625.00. L'avis comprend la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable mat茅rielle non divulgu茅e et fait r茅f茅rence aux dispositions d'un plan de trading/r猫gle 10b5-1, sans pr茅ciser de date d'adoption du plan.
Quest Diagnostics (DGX) 鈥� Eine Form-144-Mitteilung weist einen geplanten Verkauf von 72 Aktien Stammaktien 眉ber Fidelity Brokerage aus (gesch盲tzter aggregierter Marktwert $12.960,00) mit einem geplanten Verkaufsdatum am 15.08.2025. Der Meldende berichtet 眉ber fr眉here Erwerbe 眉ber das ESPP des Unternehmens: 12 Aktien erworben am 31.01.2022 und 60 Aktien erworben am 19.07.2024, beide bar bezahlt. Die Einreichung offenbart zudem einen k眉rzlichen Verkauf durch Thomas P. Plewman von 5.535 Aktien am 06.08.2025 mit Bruttoerl枚sen von $968.625,00. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind, und verweist auf Bestimmungen zu einem Handelsplan/Rule 10b5-1, nennt jedoch kein Datum der Plan眉bernahme.
- Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale, acquisition history, and recent insider transactions, meeting Rule 144 notice requirements.
- Small proposed sale: The current filing shows a proposed sale of only 72 shares, a modest amount relative to the previously reported sale.
- Recent large insider sale: Thomas P. Plewman sold 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00, which may draw investor scrutiny.
- No 10b5-1 plan date provided: The filing references trading-plan provisions but does not state a plan adoption date, reducing clarity on whether sales were pre-planned.
Insights
TL;DR: Small planned sale (72 shares) contrasts with a recent larger insider sale (5,535 shares for $968,625), which may attract investor attention.
The Form 144 documents a modest proposed disposition of 72 shares via Fidelity with an indicated aggregate market value of $12,960.00 and confirms prior ESPP purchases totaling 72 shares. Separately, a substantial sale by Thomas P. Plewman on 08/06/2025 of 5,535 shares for $968,625.00 is reported as securities sold during the past three months. From a trading-volume perspective the 5,535-share sale is materially larger than the current proposed sale and represents concrete insider liquidity. The filing contains no earnings, operational updates, or statements of intent for proceeds, so economic interpretation should be limited to disclosure of trading activity.
TL;DR: Disclosure is compliant but lacks any stated 10b5-1 plan date; recent insider sale may prompt governance questions.
The document fulfills Rule 144 notice requirements by listing the securities to be sold, acquisition history via ESPP, and recent insider sales. It includes the customary certification that no undisclosed material adverse information exists. The form does not indicate a Rule 10b5-1 plan adoption date or other trading-plan details, which would clarify whether sales were pre-planned versus discretionary. For governance transparency, investors often prefer explicit plan dates; their absence limits interpretability of insider intent.
Quest Diagnostics (DGX) 鈥� Un avviso Form 144 indica la proposta di vendita di 72 azioni ordinarie tramite Fidelity Brokerage (valore di mercato aggregato stimato $12.960,00) con data approssimativa di vendita il 15/08/2025. Il dichiarante segnala acquisti precedenti tramite l'ESPP dell'azienda: 12 azioni acquistate il 31/01/2022 e 60 azioni acquistate il 19/07/2024, entrambe pagate in contanti. La comunicazione riporta anche una recente vendita da parte di Thomas P. Plewman di 5.535 azioni in data 06/08/2025 per proventi lordi pari a $968.625,00. L'avviso include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali negative non divulgate e menziona disposizioni relative a un piano di trading/Rule 10b5-1, senza per貌 indicarne la data di adozione.
Quest Diagnostics (DGX) 鈥� Un aviso Form 144 muestra una propuesta de venta de 72 acciones ordinarias a trav茅s de Fidelity Brokerage (valor de mercado agregado aproximado $12,960.00) con fecha aproximada de venta el 15/08/2025. El declarante informa adquisiciones previas mediante el ESPP de la compa帽铆a: 12 acciones adquiridas el 31/01/2022 y 60 acciones adquiridas el 19/07/2024, ambas pagadas en efectivo. La presentaci贸n tambi茅n divulga una venta reciente por parte de Thomas P. Plewman de 5,535 acciones el 06/08/2025 por ingresos brutos de $968,625.00. El aviso incluye la declaraci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada y hace referencia a disposiciones de un plan de negociaci贸n/Rule 10b5-1, sin especificar la fecha de adopci贸n del plan.
Quest Diagnostics (DGX) 鈥� Form 144 瓿奠嫓电� Fidelity Brokerage毳� 韱淀暣 氤错喌欤� 72欤�毳� 毵る弰頃� 鞓堨爼鞛勳潉 氤挫棳欤茧┌(雽�霝� 頃╈偘 鞁滉皜 齑濎暋 $12,960.00) 毵る弰 鞓堨爼鞚检潃 2025-08-15搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛惖鐢 須岇偓 ESPP毳� 韱淀暣 鞚挫爠鞐� 旆摑頃� 雮挫棴鞚� 氤搓碃頄埖鐢雿�, 12欤�电� 2022-01-31鞐�, 60欤�电� 2024-07-19鞐� 順勱笀鞙茧 旆摑頄堨姷雼堧嫟. 鞝滌稖靹滌棎电� 霕愴暅 Thomas P. Plewman鞚� 2025-08-06鞐� 5,535欤�毳� 毵る弰頃� 齑濎垬鞚� $968,625.00毳� 鞓Π 靷嫟鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 瓿奠嫓电� 毵る弰鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 響滌鞝侅溂搿� 歆勳垹頃橁碃 鞛堨溂氅�, 瓯半灅瓿勴殟/Rule 10b5-1 臁绊暛鞚� 鞏戈笁頃橂倶 瓿勴殟 毂勴儩鞚检潃 氇呾嫓頃橃 鞎婌晿鞀惦媹雼�.
Quest Diagnostics (DGX) 鈥� Un avis Form 144 indique un projet de vente de 72 actions ordinaires via Fidelity Brokerage (valeur de march茅 agr茅g茅e approximative $12,960.00) avec une date de vente approximative au 15/08/2025. Le d茅clarant signale des acquisitions ant茅rieures via le plan ESPP de la soci茅t茅聽: 12 actions acquises le 31/01/2022 et 60 actions acquises le 19/07/2024, toutes deux pay茅es en esp猫ces. Le d茅p么t r茅v猫le 茅galement une vente r茅cente par Thomas P. Plewman de 5 535 actions le 06/08/2025 pour des produits bruts de $968,625.00. L'avis comprend la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable mat茅rielle non divulgu茅e et fait r茅f茅rence aux dispositions d'un plan de trading/r猫gle 10b5-1, sans pr茅ciser de date d'adoption du plan.
Quest Diagnostics (DGX) 鈥� Eine Form-144-Mitteilung weist einen geplanten Verkauf von 72 Aktien Stammaktien 眉ber Fidelity Brokerage aus (gesch盲tzter aggregierter Marktwert $12.960,00) mit einem geplanten Verkaufsdatum am 15.08.2025. Der Meldende berichtet 眉ber fr眉here Erwerbe 眉ber das ESPP des Unternehmens: 12 Aktien erworben am 31.01.2022 und 60 Aktien erworben am 19.07.2024, beide bar bezahlt. Die Einreichung offenbart zudem einen k眉rzlichen Verkauf durch Thomas P. Plewman von 5.535 Aktien am 06.08.2025 mit Bruttoerl枚sen von $968.625,00. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind, und verweist auf Bestimmungen zu einem Handelsplan/Rule 10b5-1, nennt jedoch kein Datum der Plan眉bernahme.
FAQ
What does Quest Diagnostics' (DGX) Form 144 report?
Who executed the recent large sale disclosed in the filing?
Were the shares being sold originally acquired through an employee plan?
Does the Form 144 state a Rule 10b5-1 trading plan adoption date?
Through which broker will the proposed 72-share sale be executed?
